Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

The effectiveness of highly active antiretroviral therapy in HIV-infected patients.

Jensen-Fangel S.

Dan Med Bull. 2004 Nov;51(4):371-92. No abstract available.

PMID:
16009063
2.

Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient.

Deeks SG, Martin JN.

AIDS. 2001 Jan 5;15(1):117-9. No abstract available.

PMID:
11192853
3.

Substitution for protease inhibitors in HIV therapy.

Mikhail E.

N Engl J Med. 2003 Dec 18;349(25):2460-1; author reply 2460-1. No abstract available.

PMID:
14689602
4.

Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.

Barreiro P, de Mendoza C, González-Lahoz J, Soriano V.

Clin Infect Dis. 2005 Sep 15;41(6):897-900. Epub 2005 Aug 1.

PMID:
16107992
5.

Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.

Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W, Ruxrungtham K; Staccato Study Team.

Antivir Ther. 2006;11(5):631-5.

PMID:
16964832
6.

A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.

Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper DA, Hirschel B; Staccato Study Group.

Antivir Ther. 2005;10(6):761-7.

PMID:
16218176
7.

Potency and durability of antiretroviral therapy.

Daar ES.

J Acquir Immune Defic Syndr. 2003 Oct 1;34 Suppl 2:S111-7. Review. No abstract available.

PMID:
14703939
8.

Adherence and potency with antiretroviral therapy: a combination for success.

Gathe J Jr.

J Acquir Immune Defic Syndr. 2003 Oct 1;34 Suppl 2:S118-22. Review. No abstract available.

PMID:
14703940
9.

Antimalarial activity of sera from subjects taking HIV protease inhibitors.

Redmond AM, Skinner-Adams T, Andrews KT, Gardiner DL, Ray J, Kelly M, McCarthy JS.

AIDS. 2007 Mar 30;21(6):763-5.

PMID:
17413699
11.

The current state of human immunodeficiency virus infection and antiretroviral care in Taiwan.

Hung CC, Chang HJ, Chen MY, Yeh KC, Hsieh SM, Chuang CY.

AIDS. 2000 Jul 28;14(11):1669-71. No abstract available.

PMID:
10983661
12.

Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.

Martínez E, Gatell JM.

AIDS. 2007 Aug 20;21(13):1829-30. No abstract available.

PMID:
17690588
13.

Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.

von Hentig N, Babacan E, Staszewski S, Stürmer M, Doerr HW, Lötsch J.

Antivir Ther. 2007;12(8):1237-46.

PMID:
18240863
14.

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.

Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.

AIDS. 2008 Jul 11;22(11):1305-12. doi: 10.1097/QAD.0b013e3282fa75b9.

PMID:
18580610
15.

HAART induces the expression of HLA-G on peripheral monocytes in HIV-1 infected individuals.

Cabello A, Rivero A, Garcia MJ, Lozano JM, Torre-Cisneros J, González R, Dueñas G, Galiani MD, Camacho A, Santamaria M, Solana R, Montero C, Kindelán JM, Peña J.

Hum Immunol. 2003 Nov;64(11):1045-9.

PMID:
14602234
16.

Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen.

Rodriguez A, Hill-Zabala C, Sloan L, Jefferson T, Yau L, Watson M, Irlbeck D, Shaefer M.

J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):127-9. No abstract available.

PMID:
16340487
17.

Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004.

Lohse N, Obel N, Kronborg G, Jørgensen LB, Pedersen C, Larsen CS, Kvinesdal B, Sørensen HT, Gerstoft J.

Antivir Ther. 2006;11(5):591-600.

PMID:
16964827
18.

An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.

Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, Rousseau F.

AIDS. 2006 Oct 24;20(16):2051-64. Review.

PMID:
17053351
19.

Preventing and managing resistance in the clinical setting.

Kuritzkes DR.

J Acquir Immune Defic Syndr. 2003 Oct 1;34 Suppl 2:S103-10. Review. No abstract available.

PMID:
14703938
20.

Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.

Palma P, Romiti ML, Cancrini C, Pensieroso S, Montesano C, Santucci MB, Bernardi S, Martino AM, Rossi P, Castelli-Gattinara G.

AIDS. 2007 Nov 30;21(18):2465-72.

PMID:
18025883

Supplemental Content

Support Center